IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.687
AS - Asia 2.556
EU - Europa 2.102
SA - Sud America 449
AF - Africa 244
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 15.045
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.621
SG - Singapore 1.250
CN - Cina 526
HK - Hong Kong 453
RU - Federazione Russa 430
IE - Irlanda 428
BR - Brasile 396
IT - Italia 272
SE - Svezia 257
DE - Germania 213
CI - Costa d'Avorio 191
GB - Regno Unito 147
UA - Ucraina 115
IN - India 87
VN - Vietnam 73
FR - Francia 50
FI - Finlandia 48
CA - Canada 34
JP - Giappone 33
BD - Bangladesh 25
KR - Corea 25
PL - Polonia 25
MX - Messico 23
AR - Argentina 22
MA - Marocco 20
BE - Belgio 19
ZA - Sudafrica 17
NL - Olanda 16
ID - Indonesia 14
EE - Estonia 13
ES - Italia 13
DK - Danimarca 11
IQ - Iraq 11
TR - Turchia 11
CO - Colombia 9
RO - Romania 7
AU - Australia 6
BG - Bulgaria 6
EC - Ecuador 6
AT - Austria 5
CZ - Repubblica Ceca 5
IL - Israele 5
KZ - Kazakistan 5
PY - Paraguay 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
EG - Egitto 4
LT - Lituania 4
PK - Pakistan 4
TN - Tunisia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
LU - Lussemburgo 3
NP - Nepal 3
SA - Arabia Saudita 3
TT - Trinidad e Tobago 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
GD - Grenada 2
IS - Islanda 2
KE - Kenya 2
LB - Libano 2
LY - Libia 2
MY - Malesia 2
OM - Oman 2
PA - Panama 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AM - Armenia 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CL - Cile 1
DO - Repubblica Dominicana 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
LI - Liechtenstein 1
LV - Lettonia 1
MN - Mongolia 1
PE - Perù 1
PH - Filippine 1
SN - Senegal 1
TH - Thailandia 1
Totale 15.045
Salva come PNG Salva come JPEG
Città #
Des Moines 1.471
Chandler 1.178
Singapore 893
Ashburn 892
Fairfield 666
Dallas 562
Hong Kong 453
Dublin 420
Wilmington 347
Boardman 319
Woodbridge 282
Houston 253
Seattle 253
Cambridge 214
Jacksonville 200
Abidjan 191
The Dalles 187
Lawrence 167
Princeton 167
New York 156
San Mateo 142
Ann Arbor 135
Beijing 131
Los Angeles 120
San Diego 100
Moscow 93
Munich 81
Washington 73
Redmond 72
Pune 65
Columbus 50
London 45
Chicago 43
São Paulo 41
Hefei 39
Council Bluffs 35
Ancona 33
Falls Church 31
Tokyo 30
Shanghai 29
Buffalo 28
Wuhan 27
Guangzhou 24
Ho Chi Minh City 24
Santa Clara 24
Turku 24
Helsinki 23
Warsaw 21
Stockholm 20
Brussels 19
Montreal 19
Norwalk 19
Turin 19
Brooklyn 18
Hanoi 18
Atlanta 17
Denver 17
Phoenix 17
Seoul 17
San Francisco 16
Jiaxing 15
Manchester 13
Boston 12
Rio de Janeiro 12
Rome 12
Brasília 11
Jakarta 10
Prescot 10
Curitiba 9
Forlì 9
Johannesburg 9
Salt Lake City 9
Centro 8
Chennai 8
Mexico City 8
Tampa 8
Dhaka 7
Edinburgh 7
Fayetteville 7
Fuzhou 7
Guarulhos 7
Poplar 7
Porto Alegre 7
Strasbourg 7
Wuxi 7
Baghdad 6
Bologna 6
Cagliari 6
Menlo Park 6
Milan 6
Nuremberg 6
Orem 6
Secaucus 6
Shenzhen 6
Southwark 6
Tolentino 6
Yiwu 6
Charlotte 5
Elk Grove Village 5
Hounslow 5
Totale 11.383
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 180
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 179
Are liver nested stromal epithelial tumors always low aggressive? 177
Immunotherapy in genitourinary cancers: Where are we going? 171
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 160
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 154
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 146
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 145
Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Randomized Phase III METEOR Trial 142
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 140
Predicting future cancer burden in the United States by artificial neural networks 135
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 134
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 129
Microbiome and cancers, with focus on genitourinary tumors 129
Exploring the Spectrum of Kidney Ciliopathies 128
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 127
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 126
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 124
An update on investigational therapies that target STAT3 for the treatment of cancer 122
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 119
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 119
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 115
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 114
Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology 114
Molecular diagnostics in uro-oncology 113
From undergraduate medical school student to visible pathologist 112
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 112
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 111
Molecular characterization of testicular germ cell tumors using tissue microdissection 111
Pd-l1 inhibitors for the treatment of prostate cancer 109
Is There a Role for Immunotherapy in Prostate Cancer? 109
Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule 107
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 106
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 106
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 105
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 105
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 105
Biphasic Tumors of the Urogenital Tract: Selected Topics 105
Bone targeting agents in patients with metastatic prostate cancer: State of the art 104
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 104
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 103
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 103
Epigenetic modifications and modulators in prostate cancer 102
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 102
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 101
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 100
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 100
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 100
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 100
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 99
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 99
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 98
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 98
Pathology and molecular updates in tumors of the prostate: towards a personalized approach. 97
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 97
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 96
The human microbiota and prostate cancer: Friend or foe? 96
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 96
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 96
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 96
Immune checkpoint inhibitors for the treatment of bladder cancer 96
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice 95
The identification of immunological biomarkers in kidney cancers 95
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 95
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 94
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer 94
Variants of Bladder Cancer: The Pathologist's Point of View 94
Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers 94
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 94
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 93
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 93
Epigenetic modulations and lineage plasticity in advanced prostate cancer 92
An update on immunotherapy in uro-oncology 92
Treating prostate cancer by antibody-drug conjugates 92
Pathology without microscope: From a projection screen to a virtual slide 91
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 91
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading 90
Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading 90
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 89
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 89
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 88
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy 88
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 88
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 87
Variants and new entities of bladder cancer 87
Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer 86
Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance 86
Renal Cell Carcinoma: genomic landscape and clinical implications 86
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 85
Immunotherapy and radiation therapy in renal cell carcinoma 85
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 85
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 85
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 84
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 84
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 84
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 83
Whole slide imaging of large format histology in prostate pathology: Potential for information fusion 83
Emerging molecular technologies in genitourinary tumors 83
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 83
Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view 82
Totale 10.587
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.416
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.416
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.741 0 0 0 0 0 762 182 186 138 200 230 43
2021/20221.512 267 171 79 23 50 179 28 90 128 116 87 294
2022/20234.130 266 288 156 313 218 1.705 3 234 680 16 178 73
2023/20241.610 282 45 138 162 248 358 22 49 5 57 24 220
2024/20252.948 376 229 35 52 103 121 226 107 750 305 259 385
2025/20262.700 396 441 441 288 1.024 110 0 0 0 0 0 0
Totale 15.280